Transcript TITLE
MOLECULAR CARCINOGENESIS • Defects in Terminal Differentiation • Defects in Growth Control • Resistance to Cytotoxicity • Defects in Programmed Cell Death CHEMICAL Body Surface R A Deactivation Excretion D Genetic Change I Activation A T Nucleus I O N Inhibition NORMAL CELL VIRUS Selective Clonal Expansion Genetic Change Genetic Change Genetic Change PREINITIATED NEOPLASTIC MALIGNANT CELL TUMOR LESION CLINICAL CANCER • Activation of Proto-Oncogenes • Inactivation of Tumor Suppressor Genes • Inactivation of Genomic Stability Genes CANCER METASTASIS 1044-CH CHRONIC INFLAMMATION AND CANCER Inherited Disease Acquired Tumor Site Risk Hemochromatosis Liver 219 Hereditary Pancreatitis Pancreas 120 Crohn’s Disease Colon 3 Ulcerative Colitis Colon 6 “Chronic infection and associated inflammation contribute to about 1/3 of cancers worldwide” -B.N. Ames, PNAS, 1995 “18% of human cancers, i.e., 1.6 million per year, are related to infection.” - B. Stewart and P. Kleihues World Cancer Report, IARC Press, p. 57, 2003 Disease Tumor Site Risk Viral Hepatitis B Hepatitis C Liver Liver 88 3 Bacterial Helicobacter Pylori Gastric PID Ovary 11 3 Parasitic S. hematobium S. japonicum Liver Fluke Urinary Bladder 2-14 Colon 2-6 Liver 14 Chemical/ Physical Acid reflex Esophagus Metabolic Disease Obesity Colon 50-100 1.5 CANCERS ASSOCIATED WITH OBESITY In Women • Breast (postmenopausal) • Endometrium • Cervical • Ovarian • Colorectal • Kidney • Liver/ Gall Bladder • Pancreatic • Esophageal • Hematopoietic Calle, E et al., NEJM 348:1625-38, 2003 In Men • Prostate • Colorectal • Kidney • Liver/Gall Bladder • Pancreatic • Esophageal • Hematopoietic 3000-CH REACTIVE NITROGEN AND OXYGEN SPECIES DERIVED FROM INFLAMMATORY CELLS Myeloperoxidase NO2- O2 N2O3 NO• Nitrous Anhydride Neutrophil O2 • Macrophage H2O2+Cl-/Br- H2O2 ONOO - CO2 ONOOCO2- Oxidation & HOCl Halogenation HOBr NO2• Oxidation & Nitration Deamination OH • NO2• Oxidation & Nitration CO3• Nitrosoperoxycarbonate Of DNA and Proteins 2786*-CH FREE RADIALS AND INFLAMMATION ROS •OH O2- • (Hydroxyl (Superoxide) radical) NO • RNS ONOO- (Nitric Oxide) (Peroxynitrite) (Nitroxyl Radical) Protein Damage Lipid Peroxidation (DNA Repair Enzymes, Caspases) DNA Damage and Mutation Nitrosamines/Deamination 8--oxo-dG 8-nitroguanine Etheno Adducts M1G Adduct S-nitrosothiol SSB’s DSB’s N2O3 MDA (malondialdehyde) 4HNE (4-hydroxynonenal) Arachidonic Acid Cascade Eicosenoids Cell Proliferation 1760-CH NITRIC OXIDE SYNTHASE Inactive cNOS Inactive cNOS Active cNOS CaM Ca+++2 CaM CaM CaM NO Citrulline L-ARGININE NO CaM iNOS CaM Always active Billiar NITRIC OXIDE DAMAGES DNA AND ACTIVATES p53 IN MCF-7 CELLS DNA DAMAGE p53 MODIFICATIONS SPER/NO p53 MCF-7 Cells P-Ser-15 P-Ser-20 P-Ser-33 P-Ser-46 P-Ser-315 P-Ser-392 K-Lys-382 2016*-CH NO-INDUCED p53 PHOSPHORYLATION TRANSACTIVATES DOWNSTREAM PROTEINS AND ENGAGES A G2/M ARREST DOWNSTREAM PROTEINS % Cells in G2/M Mitotic Index 2122A*-CH INDUCIBLE NITRIC OXIDE SYNTHASE (NOS2) AND CYCLOOXYGENASE-2 (COX2) INTERACTIONS IN HUMAN CARCINOGENESIS Hypoxia HIF1a NOS2 • Cytokines e.g., IL-1b TNF-a Hypoxia Genomic instability NO • • p53 Selective Clonal Expansion DNA damage Mutant p53 Lipid Peroxidation COX2 NFB K-ras p53 Prostaglandins (e.g., PGE2) Apoptosis 1079A*-CH 1909-CH VENN DIAGRAM OF 1396 “p53-DEPENDENT” GENES MODULATED BY CELLULAR STRESS NO Hypoxia H 2 O2 29 666 genes HU 139 genes 34 35 14 33 40 5 14 11 140 genes HU 4 7 225 genes Hypoxia (T-test at p<0.001 for each treatment and time point) 2978-CH EXAMPLES OF CHRONIC INFLAMMATORY CONDITIONS ASSOCIATED WITH INCREASED p53 MUTATION LOAD • ULCERATIVE COLITIS • HEMOCHROMATOSIS • WILSON DISEASE • VIRAL HEPATITIS Absolute Mutation frequency x 10 -7 p53 MUTATION LOAD IS INCREASED IN ULCERATIVE COLITIS 30 G TO A (CpG SITE OF CODON 248 ) UC vs. Non-UC (p < 0.001) C TO T (CODON 247) 20 UC vs. Non-UC ( p < 0.001) 10 0 ULCERATIVE NORMAL COLITIS CONTROL 054-PH 1908-CH Transcription Senescence p53 Cell Cycle Checkpoints (1979) Programmed Development Cell Death • DNA Repair • Homologous Recombination • Chromosomal Segregation 509B*-CH p53 IS AT THE CROSSROADS OF CELLULAR STRESS RESPONSE PATHWAYS DNA Damage Hypoxia NOS2 Oncogene Activation E2F p14ARF ATM, ATR, CHK2 p53 mdm2 Cell Cycle Checkpoints DNA Repair Apoptosis Senescence p21WA F1 14-3-3s Gadd45 GADD45, p48, p53R2 APE1, Pol b PUMA, NOXA, BAX, p21WAF1 Apaf1, XPB, XPD, WRN, BLM Others 1306I*-CH EXAMPLES OF p53 NEGATIVE FEEDBACK LOOPS • Posttranslational Modification and Proteolytic Cleavage p53 MDM2 Ubiquitination Oliver et al., Nature 362: 857, 1993 Wu et al., Genes Dev. 7: 1126, 1993 • ATM-Dependent DNA Damage Pathway CHK2 Kinase p53 Phosphorylation Transrepression Matsui et al., J. Biol. Chem. in press, 2004 • Nitric Oxide Pathway Inducible Nitric Oxide Synthase DNA Damage Transrepression Forrester et al., PNAS 93: 2442, 1996 Ambs et al., PNAS 95: 8823, 1998 p53 2900-CH MODEL OF CELLULAR STRESS INDUCED p53 ACTIVATION AND APOPTOSIS Mitochondrial Depolarization p53 PUMA, NOXA, BAX, p53AIP1 PIG3 Ferredoxin reductase Cytochrome C + ProCaspase 9 + APAF1 MnSOD O•2 GPX1 H 2 O + O2 H 2 O2 2+ CAT Fe Lipid Peroxidation EXECUTIONER CASPASES APOPTOSOME 1996A*-CH APAF-1 IS A TRANSCRIPTIONAL TARGET OF p53 IN DNA DAMAGE-INDUCED APOPTOSIS p53 Apoptotic stimuli RE PUMA, NOXA, p53AIP1, Bax Mitochondrial depolarization Apoptosome Pro-caspase 9 Apaf-1 Cytochrome C Caspase 3 APOPTOSIS 1917*-CH CELL DEATH Programmed Non-programmed 1935-CH MUTATIONAL SPECTRA OF THE p53, APC, ATM AND BRCA-1 GENES IN ALL HUMAN CANCERS p53 Frameshift 9% Splice site 2% In Frame Del/Ins. 2% Silent 5% (n=15,122) APC Nonsense 7% Nonsense 32% Frameshift 51% Missense 75% ATM Frameshift 56% (n=1,451) Missense 4% Silent 9% Splice site 4% BRCA-1 (n=617) Nonsense 14% Missense 28% In Frame Del/Ins. 2% (n=3,703) Nonsense 11% Frameshift 54% Missense 30% Splice site 5% 797B-CH EXAMPLES OF p53 MUTATION HOTSPOTS ASSOCIATED WITH CARCINOGEN EXPOSURE Tobacco Smoking Lung ,Codon 157 400 Hemochromatosis Liver, Codon 220 Aflatoxin B1 and HBV Liver, Codon 249 249 300 G:C to T:A 98% 200 G:C to T:A 78% A:T to G:C 100% 157 100 Missense Sunlight Skin, Codon 281 281 220 CC to TT 100% 0 17-29 97 EVOLUTIONARILY CONSERVED N 292 324 352 C Transactivation Domain Sequence-Specific DNA Binding Domain Oligomerization and Nuclear Localization and Export Domains 567L-CH HYPOTHESIS: • p53 mutation hotspots in clonally derived human cancers reflect the preferential: • sites of carcinogen-DNA adduct formation in the gene • sites of slow repair of DNA damage • mutagenic potential of certain carcinogen-DNA adducts • pathobiological effects of the p53 mutant leading to a selective clonal expansion advantage, including “gain of function” or an increase in genomic instability 1156-CH WORLDWIDE p53 MUTATIONAL SPECTRA IN HCC FROM DIFFERENT GEOGRAPHICAL AREAS North America N=15 Western Europe N=82 Japan N=242 China N=171 Taiwan N=113 Africa N=28 Incidence of HCC per 100,000 < 3.3 < 9.0 p53 MUTATION DIAGRAM Del + ins. G:C to C:G A:T to C:G G:C to T:A < 15.0 A:T to G:C < 5.6 < 98.9 A:T to T:A G:C to A:T CpG G:C to A:T Non-CpG 2115-CH ASSESSMENT OF CAUSATION BY THE BRADFORD-HILL CRITERIA HYPOTHESIS: Dietary aflatoxin B1 exposure can produce 249ser (AGG->AGT) p53 mutations during human liver carcinogenesis • STRENGTH OF ASSOCIATION • Consistency • Positive correlation in 3 different ethnic populations on 3 continents • Temporality • 249ser p53 mutant cells observed in non-tumorous liver in high HCC incidence geographic areas • Specificity • 249ser p53 mutations are uncommon in other cancer types • 249ser p53 mutation in serum DNA is a biomarker of liver cancer risk From: Hussain and Harris, Cancer Res. 58: 4023-37, 1998 926C-CH ASSESSMENT OF CAUSATION BY THE BRADFORD-HILL CRITERIA HYPOTHESIS: Dietary aflatoxin B1 exposure can produce 249ser (AGG->AGT) p53 mutations during human liver carcinogenesis • BIOLOGIC PLAUSIBILITY • AFB1 is a potent carcinogen in rodents, monkeys and humans • AFB1 is enzymatically activated by human hepatocytes to 8,9-AFB1 oxide that binds to DNA, including the 3rd base (G) at codon 249 • AFB1 exposure to human liver cells in vitro produces codon 249ser p53 mutations • 249ser p53 expression inhibits apoptosis and p53-mediated transcription and enhances liver cell growth rates in vitro From: Hussain and Harris, Cancer Res. 58: 4023-37, 1998 926D-CH p53 CODON 249ser MUTANT IN SERUM DNA AND SERUM HBVSAg ARE BIOMARKERS OF LIVER CANCER RISK • HBSAg/249p53 mutant minus/minus plus/minus minus/plus plus/plus RR(95%CI) 1 10(5-20) 13(5-35) 399(49-3272) Kirk, GD et al., Proc. 11th Int. Symposium on Viral Hepatitis and Liver Diseases, Sydney, 2003. FORTY PERCENT OF LIVER CANCER IN QIDONG, PRC IS ATTRIBUTABLE TO AFLATOXIN DIETARY EXPOSURE Ming, l et al., Hepatology 36: 1214-20, 2002. COLORECTAL CARCINOGENESIS • SPORADIC: Normal Mucosa Mutation K-ras APC b-catenin p53 Adenomatous ~55% Polyps Carcinoma ~45% 85% ~10% • ULCERATIVE COLITIS ASSOCIATED: Ulcerative Colitis Dysplasia Carcinoma ~15% 6% ?% ~55% 885-CH EXAMPLES OF GENETIC LESIONS IN BRONCHIAL DYSPLASIA, CARCINOMA-IN-SITU AND LUNG CARCINOMA Lesion • LOH • 3p12, 14, 21 • 9p21 • 17p13 • p53 (p17p13) • p16 (9p21) • Telomerase • Ki-ras • FHIT (3p14) • Rb Dysplasia CIS Carcinoma 1049-CH